reports
Avacta Announces Preclinical and Translational Presentations of pre|CI...
Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference LONDON and PHILADELPHIA, March 17, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced it will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA. Details of the two present...
- Franc Gregori
- Lala Gregorek
Trinity Delta Lighthouse: Avacta
Trinity Delta view: Lead compound, faridoxorubicin, has provided proof-of-concept for Avacta’s pre|CISION PDC platform and specifically FAP-activation at the tumour site; however, in our view, greater value lies in next-generation programmes, including AVA6103. AVA6103 is on the cusp of entering the clinic: Phase Ia is due to start in Q126 in four cancer indications (cervical, gastric, pancreatic, small cell lung cancer) identified in conjunction with Tempus AI. This partnership, as well as the ...
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantage...
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® Clinical trial with AVA6103 is expected to be initiated in Q1 2026 LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today pub...
Avacta appoints Francis Wilson as Chief Scientific Officer
Avacta appoints Francis Wilson as Chief Scientific Officer LONDON and PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer. Since joining Avacta in September 2022 as Vice President of Chemistry, Francis has demonstrated his extensive expertise and experience in the chemistry field, particularly in the development of the Company's pre|CISION® platform. Francis has b...
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Progr...
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program Cardiac dosing limit removed and path forward to dose selection identified LONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing le...
Avacta Announces U.S. Food and Drug Administration Clearance of the In...
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103) The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Dr...
- Franc Gregori
- Lala Gregorek
Avacta: pre|CISION prospects build
Avacta is approaching a defining period, with the imminent Phase I start of its second asset AVA6103 (FAP-EXd), a sustained release pre|CISION-exatecan conjugate. Initial data by year-end, as well as first breast cancer data for lead asset faridoxorubicin (AVA6000, FAP-Dox) could crystallise partnering interest. The utility, and value, of the pre|CISION platform is becoming clearer as growing preclinical and clinical data confirm its ability to improve the therapeutic index of many highly potent...
Avacta Announces Year-end Trading Update
Avacta Announces Year-end Trading Update LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published a trading update for the year ended December 31, 2025. The Company made excellent progress during 2025, developing its unique industry-leading technology platform, pre|CISION®, with two programs anticipated to be in clinical development in 2026. The Company raised £22.5m in equity during 2025 to support the investment in its progr...
- Franc Gregori
- Lala Gregorek
Trinity Delta Lighthouse: Avacta
Trinity Delta view: Updated SGC data in 30-patients confirm that the efficacy and safety signals seen in Phase Ia are consistent and meaningful. Maturing data from the Phase 1b cohort will guide design of the Phase II/III registration study in SGC. Whilst clearly important, we view the real significance of this encouraging data as providing the proof-of-concept for Avacta’s FAP-targeted pipeline. Although faridoxorubicin has a clear clinical, and commercial, role, the greater value of Avacta’s p...
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically mean...
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platfo...
Avacta presents first preclinical data from dual payload pre|CISION® m...
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and maximize tumor control LONDON and PHILADELPHIA, Oct. 25, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced the presentation of...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta Lighthouse: Avacta
Trinity Delta view: Although addressing attractive, and commercially relevant, indications, we view faridoxorubicin’s (FAP-Dox, previously AVA6000) primary role as being proof-of-concept demonstration of FAP-targeted biotherapeutics. The versatility and broad potential of Avacta’s pre|CISION platform, with the ability to selectively activate potent drugs in the TME, should lead to a deep pipeline of novel targeted therapeutics. The successful £16m placing removes funding uncertainty and allows m...
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubi...
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m² LONDON and PHILAD...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta Lighthouse: Avacta
Trinity Delta view: These preclinical data once again provide valuable insights into the versatility and broad potential of Avacta’s pre|CISION platform. The proof-of-concept of FAP-targeted biotherapeutics will be demonstrated through its lead clinical candidate, faridoxorubicin (FAP-Dox, previously AVA6000), but we believe this should be viewed as the first in a pipeline of novel therapeutics that can be selectively activated in the TME, thus reducing toxicity and improving patient outcomes. W...
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the...
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, today announces that the Company will present data on its firs...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Avacta: Key faridox data and FAP-EXd Phase I start on the horizon
Phase I data from Avacta’s lead pre|CISION asset, faridoxorubicin (formerly FAP-Dox, AVA6000) continues to mature, with presentation of full Phase Ia dose escalation data upcoming at the European Society of Medical Oncology (ESMO) 2025 meeting. Further data from salivary gland cancer (SGC) patients enrolled in the Phase Ia/Ib dose escalation and expansion cohorts are expected by year-end, with similar data in TNBC (triple negative breast cancer) following in H126. These data, along with addition...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta Lighthouse: Avacta
Trinity Delta view: In our view, the amended CB terms indicate management confidence in their ability to secure funds to advance Avacta’s pre|CISION assets through clinical development. This funding is likely to come from a variety of sources including partnerships, strategic investment, and/or an equity raise, and could be catalysed by key data readouts slated for the next 12 months: Phase I FAP-Dox SGC results in H225 (potentially at ESMO 2025) and TNBC data in H126. Appetite for Avacta equity...
Avacta to Present New FAP Dox (AVA6000) Data at the European Society f...
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjug...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 02/07/2025
* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and Closing Price on prior day to Publication. Dish of the day Admissions: Today, none. Yesterday, Elixirr International (ELIX.L) transferred from the AIM to Main Market. Delistings: Today, Aquis Exchange (AQX.L) and Kinovo (KINO.L) delisted from AIM. Yesterday, Invinity Energ...
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer ...
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company’s clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Boga...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.